Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD1) or programmed death-ligand 1 (PD-L1) have revolutionized the pattern of anti-tumor treatment with improved survival in multiple cancer types [1, 2]. Here, CD274 is linked to neoplasm.